Study PXN110448: A Dose-Response Study of XP13512 [gabapentin enacarbil], Compared With Concurrent Placebo Control and LYRICA (Pregabalin), in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN).

Trial Profile

Study PXN110448: A Dose-Response Study of XP13512 [gabapentin enacarbil], Compared With Concurrent Placebo Control and LYRICA (Pregabalin), in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN).

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2013

At a glance

  • Drugs Gabapentin enacarbil (Primary) ; Pregabalin
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 27 Apr 2009 Results reported in a GlaxoSmithKline media release.
    • 27 Apr 2009 Primary endpoint "Change from baseline in mean 24-hour average pain intensity score based on an 11-point Pain Intensity Numeric rating Scale (PI-NRS)" has not been met according to a GlaxoSmithKline media release.
    • 26 Feb 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top